BoxOne Ventures

Juvena Therapeutics is a computationally-driven biopharmaceutical company focused on unlocking the therapeutic potential of secreted proteins to develop life-saving biologics for chronic and age-related diseases.

Nutrumami provides a new form of multi-functional ingredients that deliver taste, texture, and nutrition in all-in-one solutions, focusing on plant-centric foods without excessive additives or animal proteins.

BlankBio.com is currently for sale. It is listed on Spaceship.com with no hidden fees. The sale includes secure checkout and quick transfer.

Xatoms is commercializing the world’s most efficient visible light-activated photocatalysts to clean polluted water from the toughest contaminants using AI and quantum chemistry.

CytoTronics is transforming cell biology discovery with high-throughput, semiconductor-based platforms that provide live cell insights with single-cell resolution across all cell types.

Guiker is a real estate operating system that redefines property ownership, offering flexible living and effortless ownership through innovative investment solutions.

Revalia Bio accelerates drug development through Human Data Trials, leveraging real human data to improve the drug discovery process before clinical trials.

Invests in disruptive, technology-focused startups; established in 1999.

Operator-heavy team of repeat entrepreneurs that disproportionately backs pre-product deep-tech moonshots addressing civilization-scale problems, applies a strict Mr. Burns test, and runs 5050 to help scientists become founders.

Pre-seed lead investor for deeply technical AI, biotech, climatetech and infrastructure startups, offering female operator-led go-to-market expertise and structured fellowships to source technical-founder deal flow. Divergent Capital is run by two female operator-investors who combine deep-tech investing experience with hands-on go-to-market expertise, and they cultivate deal flow through structured fellowships targeting students and emerging investors in their technical-founder network.

Very-early investor using an impact-arbitrage strategy in high-impact companies, combining a solo-GP and 42 global venture partners to secure 69% top-tier follow-ons while pursuing top-decile returns and social impact.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.